Latest Advances in Lung Cancer Research

A new study offers hope for people with EGFR lung cancer whose treatment stopped working. Published in the New England Journal of Medicine, it found that osimertinib and savolitinib together beat chemotherapy.

Tarlatamab small cell lung cancer research just took a major step forward. A new study in the New England Journal of Medicine found that adding tarlatamab to standard maintenance treatment helped patients live much longer.

Patients with ROS1 lung cancer have a new option. On July 22, 2026, the FDA approved zidesamtinib, sold as Jideytro. The maker is Nuvalent, Inc.

Discover why 9 in 10 lung cancer patients miss out on clinical trial discussions and how asking one key question early can unlock life-saving options.

Large trial finds nivolumab after lung cancer surgery didn’t improve survival or prevent recurrence compared to observation alone.

New drug ivonescimab cut death risk 34% in lung cancer trial, outperforming standard immunotherapy plus chemo combination.

Selpercatinib cut lung cancer recurrence risk by 83% in patients with rare RET-positive early-stage non-small cell lung cancer.

New data shows elisrasib provides strong, lasting tumor responses for advanced lung cancer patients, including those who failed previous KRAS-targeted treatments.

New pill sevabertinib (Hyrnuo) shrinks tumors in 70% of patients with rare HER2-mutated lung cancer. Learn about this FDA fast-tracked breakthrough.

A new Phase 3 trial finds Ivonescimab paired with chemotherapy delayed lung cancer progression by 40 % compared to a PD-1 inhibitor combo.

FDA fast-tracks ZL-1310, a promising targeted therapy showing 74% response rate in advanced small cell lung cancer patients with limited treatment options.